Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from New Ray Medicine International Holding Ltd. ( (HK:6108) ).
New Ray Medicine International Holding Ltd. announced supplemental information to its 2024 annual report, highlighting its investment in Shengzhou Xin Rui Wan Ma, which represents 5.9% of the Group’s total assets. This investment is held through a 39% stake in New Ray Wanma, the ultimate holding company of Shengzhou Xin Rui Wan Ma, indicating a strategic focus on maintaining significant investments in key pharmaceutical ventures.
More about New Ray Medicine International Holding Ltd.
New Ray Medicine International Holding Ltd. is a company incorporated in Bermuda with limited liability, primarily engaged in the pharmaceutical industry. The company, along with its subsidiaries, focuses on investments and holdings in various pharmaceutical ventures.
Average Trading Volume: 277,601
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$63.53M
See more insights into 6108 stock on TipRanks’ Stock Analysis page.